Signalife, Inc.
OTC Bulletin Board : SGAL

November 11, 2008 08:30 ET

Legend Willie Gault Speaks at Campus of National Institutes of Health

LOS ANGELES, CALIFORNIA--(Marketwire - Nov. 11, 2008) - Signalife, Inc. (OTCBB:SGAL) announced today that its Chief Executive Officer, Willie Gault, recently gave a speech to physicians, scientists and health care providers at the National Library of Medicine - on the campus of the National Institute of Health - regarding the inability of all ECG devices, except the company's Fidelity 100, to detect pathology in a manner calculated to accurately screen and detect pathologies in the manner outlined by the American Heart Association.

Mr. Gault stated: "We have appreciated being invited by the National Library of Medicine to participate at educational and life saving events at which licensed physicians can see the data regarding the Fidelity 100 and to learn the truth about the condition of their patient's hearts. Anything I can give back to educate the experts about what I am witnessing, is something I will always gladly do and with great honor."

According to Mr. Gault: "Currently, certain patients and physicians who have been tested on the Fidelity 100 have reported that the screening has saved their lives. These range from youths to adults, who have been unable to detect pathology through existing devices and learned of their illness while the physician personnel conducted screenings utilizing the Fidelity 100 heart monitor."

At the event, held on the NIH campus, Mr. Gault warned that one key current standard of cardiovascular disease- detection (the ECG system) - much like the pre-mammogram-devices for breast cancer decades ago - has weaknesses that are "dirty little secrets." "We need to change and do the right thing for people not only in America but around the world. We must make a change because our current system is not working. People are dying at a staggering rate, in fact the American Heart Association (AHA) data shows that approximately every 30 minutes someone in America dies of heart disease. Case in point, Tim Russert, allegedly had an ECG test weeks before his death, Todd Bell, 46 (NFL athlete) had an ECG test 2 weeks before his death of heart disease, David Little, 44 (NFL athlete) had an ECG test two weeks before his death of heart disease, and countless other athletes and the general public under the age of 50 who died of heart disease before their time had the same fate. According to AHA guidelines, current ECG devices use a system called "computer averaging" - i.e., not clear uninterrupted data. In other words, the health care system, along with its inferior devices, are guessing on your life with current standard ECG equipment. Only one machine, the Fidelity 100, by Signalife, Inc., meets the AHA guidelines and has the clear uninterrupted data to catch all these pathologies that the ECG guesses at and often misses."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. The company uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is publicly traded OTC Bulletin Board and the Pink Sheets under the symbol SGAL. The company will shortly be changing its name to HeartTronics, Inc. The website for the company is http://www.HeartTronics.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife' technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring, the compliance with purchase orders, payment for parts making up orders receiving by the company and other biomedical devices incorporating Signalife' technology. Additionally, Signalife has been sued in various class action lawsuits and has filed a lawsuit against alleged naked short sellers (and others, including the plaintiff's counsel in one class action matter), some of whom have since gone out of business for alleged naked short selling and other risky derivatives trading. These matters may negatively impact the company or - possibly - may have the reverse impact. The company and certain of its agents and prior agents are represented in defense of the class action lawsuits - and perhaps in other matters from time to time -- by the national law firm of Akin Gump Strauss Hauer & Feld LLP with respect to these matters. While the company believes these class action lawsuits lack merit and may be frivolous, the presence of the matters creates an obvious risk to the company. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife' filings with the Securities and Exchange Commission.

Contact Information

  • Signalife, Inc.
    Willie Gault
    co-CEO
    (818) 432-4560